Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KL-A167 in Relapsed or Refractory Classical Hodgkin's Lymphoma
NCT03580564Phase 2Completed
- Sponsor
- Kelun-Biotech
- Start
- Aug 2018
- Primary completion
- Aug 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tagitanlimab in classical Hodgkin lymphoma (cHL), sponsored by Kelun-Biotech. Started Aug 2018; status: completed.
02
Drugs
tagitanlimab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT03580564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03580564.